Abstract
The role of lymphocytes in the pathogenesis of bullous pemphigoid was examined by assaying the blister fluid obtained from bullous pemphigoid patients for the presence of the lymphokine, lymphotoxin. Blister fluids from six bullous pemphigoid were assayed on L-929 target cells for the presence of cytolytic molecules in the standard lymphotoxin assay. Three of six blister fluids obtained from bullous pemphigoid patients and one linear IgA bullous dermatosis patient contained significant levels of cytolytic activity. Control blister fluids from suction blisters, herpes, pemphigus, and toxic epidermal necrolysis patients did not contain cytolytic activity. Serum from five bullous pemphigoid patients also had no cytolytic activity. Neutralization studies using rabbit anti-α-lymphotoxin demonstrated that 54 to 88% of the cytolytic activity found in bullous pemphigoid blister fluid was due to α-lymphotoxin. These results indicate that lymphotoxin is locally released in the skin of bullous pemphigoid lesions and is detectable in blister fluids.
Similar content being viewed by others
References
Sams WM Jr, Gleich GJ: Failure to transfer bullous pemphigoid with serum from patients. Proc Soc Exp Biol Med 136:1027–1031, 1971
Sams WM Jr, Jordon RD: Correlation of pemphigoid and pemphigus antibody titers with disease activity. Br J Dermatol 84:7–13, 1971
Dubertret L, Bertaux B, Fosse M, Touraine R: Cellular events leading to blister formation in bullous pemphigoid. Br J Dermatol 104:615–624, 1980
Gammon WR, Lewis DM, Carlo JR, Sams WM, Wheeler CE: Pemphigoid antibody mediated attachment of peripheral blood leukocytes of the dermal-epidermal junction of human skin. J Invest Dermatol 75:334–339, 1980
Center DM, Austen KA, Wintraub BU: Identification of chemoattractant activity for lymphocytes in bullous pemphigoid bullous fluid. Transact Assoc Am Phys 76:242–252, 1978
Spofford B, Daynes RA, Granger GA: Cell mediated immunityIn vitro: A highly sensitive assay for human lymphotoxin. J Immunol 112:2111–2116, 1974
Yamamoto RS, Hiserodt JC, Lewis JE, Carmack CE, Granger GA: The human LT system. II. Immunological relationships of LT molecules released by mitogen activated human lymphocytesin vitro. Cell Immunol 38:403–416, 1978
Fair DS, Jeffes EWB III, Granger GA: Release of LT molecules with restricted physical heterogeneity by a continuous human lymphoid cell linein vitro. Immunochemistry 16:186–190, 1979
Harris PC, Yamamoto RS, Crane J, Granger GA: The human LT serum X. The initial form released by T-enriched lymphocytes is 150,000 M.W., associated with small monolytic components, and can dissociate into smaller alpha, beta and gamma M.W. classes. J Immunol 126:2165–2170, 1981
Granger GA, Shimizu I, Harris L, Anderson J, Horn P: Detection of lymphotoxinsin vitro I specific identification of short-lived activity in the plasma of various human patients employing rabbit anti-human LT serain vitro. Clin Immunol Immunopathol 10:104–115, 1978
Baba T, Sonozak H, Seki K, Uchiyama M, Ikesawa Y, Torisu M: An eosinophil chemotactic factor present in blister fluids of bullous pemphigoid patients. J Immunol 116:112–116, 1976
Naito K, Morioka S, Ogawa H: The pathogenic mechanisms of blister formation in bullous pemphigoid. J Invest Dermatol 79:303–306, 1982
Granger GA, Yamamoto RS, Fair DS, Hiserodt JC: The human LT system. I. Physical-chemical heterogeneity of LT molecules released by mitrogen activated human lymphocytesin vitro. Cell Immunol 138:388–402, 1978
Colley DG: Eosinophils and immune mechanisms: I. Eosinophil Stimulation Promoter (ESP): A lymphokine induced by specific antigen or phytohemagglutinin. J Immunol 110:1419–1423, 1973
Anhalt GJ, Bahn CF, Labib RS, Voorhees JJ, Sugar A, Diza LA: Pathogenic effects of bullous pemphigoid autoantibodies on rabbit corneal epithelium. J Clin Invest 68:1097–1101, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jeffes, E.W.B., Yamamoto, R.S., Ahmed, A.R. et al. Lymphotoxin detected in the blister fluid of bullous pemphigoid patients. J Clin Immunol 4, 31–35 (1984). https://doi.org/10.1007/BF00915284
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00915284